Antibodies to human angiopoietin-like protein 3: a patent evaluation of WO2012174178

• Published in: Expert opinion on therapeutic patents Vol. 24; no. 1; p. 113
• Main Authors: Nakajima, Katsuyuki, Kobayashi, Junji
• Format: Journal Article
• Language: English
• Published: England 01.01.2014
• Subjects: Angiopoietin-like Proteins; Angiopoietins - antagonists & inhibitors; Angiopoietins - immunology; Animals; Antibodies - therapeutic use; Biomarkers - blood; Cholesterol - blood; Cholesterol, HDL - blood; Disease Models, Animal; Drug Design; Dyslipidemias - blood; Dyslipidemias - diagnosis; Dyslipidemias - drug therapy; Dyslipidemias - enzymology; Humans; Hypolipidemic Agents - therapeutic use; Legislation, Drug; Lipoprotein Lipase - antagonists & inhibitors; Lipoprotein Lipase - metabolism; Patents as Topic; Triglycerides - blood
• ISSN: 1744-7674
• DOI: 10.1517/13543776.2013.842555

The patent WO2012174178 claims the effect of a fully human antibody or antigen-binding fragment of a human antibody which specifically binds and neutralizes, inhibits, blocks, abrogates, reduces or interferes with the activity of human angiopoietin-like protein 3 (hANGPTL3). The effects of human anti-hANGPTL3 mainly inhibit lipoprotein lipase activity and decrease triglyceride levels. In addition, it reduces plasma TC and high-density lipoprotein cholesterol in normal mice and mice with hyperlipoidemia and mimics the plasma profile of human familial combined hypolipidemia. The antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and other dyslipidemias. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject to prevent or treat abnormal lipid metabolism which causes or enhances the induction of cardiovascular diseases.